Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN): 4 pipeline candidates · 3 upcoming catalysts · ~68 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
68.4 months
D/E 0.03 · 3% dilution
Lead: Phase 1
4 candidates
3 upcoming, next in ~204d
0 buys · 27 sells (180d)
A transparent, data-derived signal for Enliven Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.1B
Cash
$132.2M
Quarterly Burn
$19.3M
Runway
68.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| elvn-001 | Phase 1 |
| elvn-002 | Phase 1 |
| eribulin | Phase 1 |
| leucovorin | Phase 1 |
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$2.24B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 7,959,538 | $312.0M |
| fmr llc | 6,829,246 | $267.7M |
| polar capital holdings plc | 5,065,933 | $198.6M |
| blackrock, inc. | 3,684,707 | $144.4M |
| commodore capital lp | 3,275,000 | $128.4M |
| vanguard capital management llc | 2,168,162 | $85.0M |
| citadel advisors llc | 1,871,515 | $73.4M |
| venrock adviser, llc | 1,726,331 | $67.7M |
| novo holdings a/s | 1,280,000 | $50.2M |
| state street corp | 1,091,106 | $42.8M |
Showing top 10 of 171 institutional holders of Enliven Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Enliven Therapeutics, Inc.'s pipeline?
Enliven Therapeutics, Inc. (ELVN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Enliven Therapeutics, Inc.'s lead drug candidate?
Enliven Therapeutics, Inc.'s most advanced tracked candidate is elvn-001 (Phase 1) for CML (Chronic Myelogenous Leukemia); Chronic Myeloid Leukemia.
What is Enliven Therapeutics, Inc.'s next catalyst?
Enliven Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: HALAVEN" — expected January 8, 2027.
What is Enliven Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Enliven Therapeutics, Inc. has approximately 68.4 months of cash runway.
What is Enliven Therapeutics, Inc.'s market capitalization?
Enliven Therapeutics, Inc.'s market capitalization is approximately $3.1B.
Get the full picture on Enliven Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.